… PD-L1 expression and its association with clinical outcomes … accuracy of prediction of PD-L1.
We also discuss the value of … , PD-L1 expression is correlated with poor clinical outcomes …

… , and only 12 patients were known to have a PD-L1 Tumor Proportion Score (TPS) of ≥50%. …
, a PD-L1 TPS of ≥50%, and an ECOG PS of 2, we sought to assess clinical outcomes to …

… suggest that PD-L1 overexpression is related to poor OS in patients with cervical cancer
and poor PFS in Asian patients with cervical cancer. This study also suggests that PD-L1 is a …

… with PD-1 and PD-L1 co-expression showed poor prognosis due to the activation of PD-1
pathway, leading to T cell exhaustion, which demonstrated the importance of PD-1/PD-L1 axis …

… immune‐inflammatory markers may represent a way to unravel the heterogeneous outcome
and assessment of patients with mNSCLC and poor PS in the immune‐oncology setting. …

… and poor outcome of anti-PD-1 therapy, with elevated baseline serum levels of PD-1 and/or
PD-L1 … This PD-1/PD-L1 combination serum biomarker was confirmed in an independent …

… we demonstrated that PD-L1 overexpression is significantly associated with poor OS and …
PD-L1 overexpression may predict poor prognosis in different cancers. Furthermore, the PD-L1 …

… 1 (PD-1) and PD-1 ligand 1 (PD-L1) has been shown to correlate with poor prognosis in …
However, the expression of PD-L1 or PD-1 ligand 2 (PD-L2) and clinical outcomes have not …

… high PD-L1 expression had poor DFS, DMFS and overall survival compared with those with
no PD-L1 … Univariate Cox proportional hazards model analysis showed that PD-L1 was an …

… prognostic value of PD-L1 in different types of cancer.63-65 Results of this study failed to
reveal a correlation between the expression of PD-L1 in tissues and a poor prognostic of OSCC …